Patients with type 2 diabetes mellitus are at the higher risk of development of on arteriosclerosis based cardiovascular diseases. Epidemiological studies have shown that diabetic dislipidemiawith hypertriglyceridemia, presence of small dense LDL subfraction, low concentration of HDL-cholesterol and increased postprandial lipemia can represent a serious threat. Several studies have found significant decrease of cardiovascular morbidity and mortality after a treatment of diabetic dislipidemia, namely by statins and fibrates. Contemporary therapeutic algorhithms of European and American professional societies for the hyperlipidemia treatment classify diabetes mellitus as an equivalent of already developed complication of atherosclerosis. Our article presents pathophysiology of the diabetic dislipidemia, recommended target values of pasma lipids in diabetic patients and an overview of present possibilities of pharmacotherapy of the diabetic dislipidemia.

        Key words: diabetic dislipidemia, cardiovascular diseases, statins, fibrates, combination therapy of hypolipidemia, polyenic fatty acids.